Company · DGX
Quest Diagnostics Incorporated
Name as listed on its exchange; filed with the SEC as QUEST DIAGNOSTICS INC.
Nasdaq's symbol directory lists DGX on the New York Stock Exchange as “Quest Diagnostics Incorporated Common Stock”.
In the 12 months to Nov 19, 2026: insiders sold on 8 occasions ($21.8M); 6 planned-sale notices; 2 filings by holders of 5% or more; 2 congressional trade disclosures; 4 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Michael E. Prevoznik, SVP & General Counsel sold $5.5M
- Catherine T. Doherty, Executive Vice President sold $5.5M
- Michael J. Deppe, SVP, Corp. Controller & CAO sold $3.1M
- Patrick Plewman, SVP for Diagnostic Services sold $3.0M
- James E. Davis, CEO and President sold $2.4M
- Karthik Kuppusamy, SVP, Clinical Solutions sold $1.6M
- DELANEY MARK E, SVP & Chief Commercial Officer sold $376K
- PFEIFFER GARY M sold $292K
Every trade (8)
- SELLMichael J. Deppe, SVP, Corp. Controller & CAO sold $3.1M
- SELLPatrick Plewman, SVP for Diagnostic Services sold $3.0M
- SELLCatherine T. Doherty, Executive Vice President sold $5.5M
- SELLPFEIFFER GARY M sold $292K
- SELLJames E. Davis, CEO and President sold $2.4M
- SELLMichael E. Prevoznik, SVP & General Counsel sold $5.5M
- SELLDELANEY MARK E, SVP & Chief Commercial Officer sold $376K
- SELLKarthik Kuppusamy, SVP, Clinical Solutions sold $1.6M
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- Plewman Patrick $3.0M
- Doherty Catherine T. $5.6M
- PFEIFFER GARY M $292K
- Davis J. E. $2.4M
- PREVOZNIK MICHAEL E $5.5M
- DELANEY MARK E $376K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- STATE STREET CORPORATION 5%
- T. Rowe Price Associates, Inc. 4.9%
Congress · STOCK Act
The Althing
Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.
- Alan Armstrong (R-OK): Purchase $1,001 - $15,000
- Alan Armstrong (R-OK): Purchase $1,001 - $15,000
Executive branch · OGE Form 278-T
Reported by the President
4 confirmed trades on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports
- Sale: QUEST DIAGNOSTICS INC $15,001 – $50,000
- Sale: QUEST DIAGNOSTICS INC $1,001 – $15,000
- Purchase: QUEST DIAGNOSTICS INC $100,001 – $250,000
- Purchase: QUEST DIAGNOSTICS INC $100,001 – $250,000
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Oct 22, 2026
- Other events Oct 22, 2026
- Departure or appointment of directors or officers Oct 6, 2026
- Results of operations and financial condition Jul 23, 2026
Lobbying · Senate LDA reports
Lobbying filed
6 quarterly lobbying reports for 2026 naming Quest Diagnostics Incorporated as the client: 2 filed by the company itself, 4 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.
- The company itself $470K
- RED+BLUE STRATEGIES $80K
- FEDERAL STREET STRATEGIES, LLC $50K
- The company itself $690K
- RED+BLUE STRATEGIES $80K
- FEDERAL STREET STRATEGIES, LLC $50K
Federal contracts · USAspending.gov
Federal contracts
30 contract awards first obligated in the last 12 months to the company or a subsidiary it lists in its 10-K, $8.6M in total obligated as USAspending.gov lists each award when Lytir last read it. Largest first.
- Department of Veterans Affairs $6.6M
- Department of Veterans Affairs $1.4M
- Department of Justice $88K
- Department of Justice $50K
- Department of Justice $50K
- Department of Justice $50K
- Department of Justice $40K
- Department of Justice $35K
- Department of Justice $31K
- Department of Justice $31K
- Department of Health and Human Services $30K
- Department of Justice $29K
- Department of Justice $25K
- Department of Justice $24K
- Department of Justice $23K
- Department of Justice $21K
- Department of Justice $17K
- Department of Justice $12K
- Department of Justice $11K
- Department of Justice $9K
- Department of Justice $8K
- Department of Justice $6K
- Department of Justice $4K
- Department of Justice $3K
- Department of Justice $3K
Showing the 25 largest of 30.
Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, USAspending.gov, OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.